Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4799594
Max Phase: Preclinical
Molecular Formula: C47H75NO17
Molecular Weight: 926.11
Molecule Type: Unknown
Associated Items:
ID: ALA4799594
Max Phase: Preclinical
Molecular Formula: C47H75NO17
Molecular Weight: 926.11
Molecule Type: Unknown
Associated Items:
Canonical SMILES: C[C@@H]1[C@H](O)[C@@H](C)/C=C\C=C/CC/C=C\C=C/C=C\C=C/[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](N)[C@@H]2O)C[C@@H]2O[C@](O)(C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)C[C@@H](O)CC(=O)O[C@H]1C)C[C@H](O)[C@H]2C(=O)O
Standard InChI: InChI=1S/C47H75NO17/c1-27-17-15-13-11-9-7-5-6-8-10-12-14-16-18-34(64-46-44(58)41(48)43(57)30(4)63-46)24-38-40(45(59)60)37(54)26-47(61,65-38)25-36(53)35(52)20-19-31(49)21-32(50)22-33(51)23-39(55)62-29(3)28(2)42(27)56/h5-6,8,10-18,27-38,40-44,46,49-54,56-58,61H,7,9,19-26,48H2,1-4H3,(H,59,60)/b6-5-,10-8-,13-11-,14-12-,17-15-,18-16-/t27-,28-,29-,30+,31+,32+,33+,34-,35+,36+,37-,38-,40+,41-,42+,43+,44-,46-,47+/m0/s1
Standard InChI Key: VQOXZBDYSJBXMA-MSHYPYPPSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: Yes | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 926.11 | Molecular Weight (Monoisotopic): 925.5035 | AlogP: 0.94 | #Rotatable Bonds: 3 |
Polar Surface Area: 319.61 | Molecular Species: ZWITTERION | HBA: 17 | HBD: 12 |
#RO5 Violations: 3 | HBA (Lipinski): 18 | HBD (Lipinski): 13 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 3.72 | CX Basic pKa: 9.11 | CX LogP: -1.94 | CX LogD: -1.94 |
Aromatic Rings: 0 | Heavy Atoms: 65 | QED Weighted: 0.18 | Np Likeness Score: 1.80 |
1. Ellen Van Damme. (2021) Screening of ~5500 FDA-approved drugs and clinical candidates for anti-SARS-CoV-2 activity, [10.6019/CHEMBL4651402] |
Source(1):